What Is Semaglutide? Dallas-Fort Worth GLP-1 Guide to Weight Loss Mechanism

How Semaglutide Works

Semaglutide is a GLP-1 receptor agonist — a synthetic version of a hormone your body already produces called glucagon-like peptide-1 (GLP-1). When you eat, your intestines naturally release GLP-1, which signals your brain that you are full and slows the rate at which food leaves your stomach [1]. Semaglutide mimics this hormone but lasts far longer in the body: natural GLP-1 breaks down in minutes, while semaglutide persists for approximately one week, which is why it is administered as a once-weekly injection [2].

The mechanism works through three primary pathways. First, appetite regulation: semaglutide activates GLP-1 receptors in the hypothalamus, the brain region that controls hunger and satiety. Patients consistently describe a reduction in food noise — the persistent background thinking about food that drives overeating. In the STEP 1 trial, participants on semaglutide 2.4mg reported a 24% reduction in hunger scores compared to placebo at week 20 [3]. Second, delayed gastric emptying: semaglutide slows the movement of food from the stomach into the small intestine, which means you feel full longer after meals. This effect is most pronounced during the first few months of treatment and moderates somewhat over time [2]. Third, insulin regulation: semaglutide stimulates glucose-dependent insulin secretion and suppresses glucagon release, which stabilizes blood sugar and reduces the spikes and crashes that trigger cravings. This is why semaglutide was first developed and approved for type 2 diabetes before its weight-loss effects were studied [4].

What semaglutide is not: it is not a stimulant. Unlike phentermine and other older weight-loss medications that increase heart rate and create a wired, jittery feeling, semaglutide does not act on adrenaline or norepinephrine pathways. It is not a traditional appetite suppressant that simply overrides hunger signals through central nervous system stimulation. Instead, it works with your body's existing hormonal system to reduce the drive to eat. This distinction matters clinically — semaglutide does not carry the cardiovascular risks associated with stimulant-based weight loss drugs, and the SELECT trial (17,604 participants) actually demonstrated a 20% reduction in major adverse cardiovascular events among semaglutide users with pre-existing heart disease [5].

In practice, here is what a weekly semaglutide injection looks like for DFW patients. The injection is subcutaneous (under the skin), typically administered in the abdomen, thigh, or upper arm using a thin 31-gauge needle. Most patients describe the injection as a mild pinch lasting 5-10 seconds. Of the 40 clinics in our DFW database, the majority administer injections in-clinic during weekly or monthly visits, while some — including Skin Damsel Aesthetics in Dallas and Pretty Heart Medspa in Frisco — provide take-home medication for self-injection [6]. Self-injection requires minimal training: a clinic visit or video tutorial covering proper injection site rotation, needle handling, and medication storage (refrigerated at 36-46°F for branded Wegovy; compounded versions may have different storage requirements depending on the compounding pharmacy) [2].

The clinical results are substantial. The STEP 1 trial (1,961 participants, 68 weeks) showed mean weight loss of 14.9% of body weight with semaglutide 2.4mg compared to 2.4% with placebo [3]. The STEP 5 extension trial (2 years) showed sustained weight loss of approximately 15.2% at 104 weeks [7]. In DFW clinics, where most patients receive compounded semaglutide rather than branded Wegovy, providers report average weight loss of 10-15% within the first 6 months. Highland Longevity in Fort Worth specifically reports an average of 15% body weight loss among its patient population, though this is clinic-reported data and has not been independently verified [6].

Semaglutide vs Tirzepatide: Head-to-Head Comparison

Tirzepatide is semaglutide's primary competitor and the other GLP-1-based weight loss medication widely available at DFW clinics. The key difference: semaglutide activates one hormone receptor (GLP-1), while tirzepatide activates two (GLP-1 and GIP, glucose-dependent insulinotropic polypeptide). This dual-agonist mechanism is why tirzepatide is sometimes called a "twincretin" [8]. The practical question for DFW patients is whether the stronger mechanism justifies the higher cost.

Sources: STEP trial program [3][7], SURMOUNT trial program [8], SemaVerified DFW clinic survey [6], Novo Nordisk and Eli Lilly published pricing. DFW compounded tirzepatide pricing estimated from clinics offering both medications.

The efficacy data favors tirzepatide. The SURMOUNT-1 trial (2,539 participants) showed mean weight loss of 20.9% with tirzepatide 15mg at 72 weeks, compared to 14.9% with semaglutide 2.4mg in the STEP 1 trial at 68 weeks [3][8]. A direct head-to-head trial (SURMOUNT-5, not yet published as of March 2026) is expected to provide the clearest comparison, but based on available data, tirzepatide produces approximately 5-9 percentage points more weight loss than semaglutide at maximum doses.

In the DFW market, 16 of 40 clinics in our database offer tirzepatide alongside semaglutide. These include Vital Wellness Texas (Dallas and Frisco locations), Genesis Lifestyle Medicine (Dallas), Renew Beauty Med Spa (Dallas and Frisco), KDI Health (Frisco), Fine Line Aesthetics (Frisco), Le Beau Visage (Frisco), Elixir 360 Health (Southlake), The Aesthetics Society (Southlake), The Stoehr Center (Frisco), Dr. Steven Camp (Fort Worth), Lone Star Medical Associates (Plano), Worthy Weight Loss (Plano), Regional Plastic Surgery (Dallas), Pretty Heart Medspa (Frisco), Vitality DPC (Farmers Branch), and Dr. Bryan Armijo (Dallas) [6]. Compounded tirzepatide costs approximately $375-500/month at these clinics — 20-60% more than compounded semaglutide.

The honest assessment: tirzepatide shows stronger weight loss in clinical trials but costs more and has less long-term safety data. Semaglutide has a longer track record, proven cardiovascular benefits (the SELECT trial), wider availability in DFW, and lower cost. For most DFW patients starting GLP-1 therapy for the first time, semaglutide is the pragmatic choice — it is more affordable, available at every clinic, and produces clinically meaningful weight loss. Patients who do not achieve adequate results on semaglutide after 6+ months, or who have a BMI above 40, may benefit from switching to tirzepatide. Discuss both options with your prescribing provider to determine which is appropriate for your clinical situation [8].

FDA Approval & Regulatory Status

Semaglutide has two distinct FDA-approved formulations, plus a compounded version that operates under a separate regulatory framework. Understanding the difference matters for DFW patients because it directly affects what you are receiving, how it is regulated, and what happens if the regulatory landscape changes [9][10].

Wegovy (semaglutide 2.4mg injection) was approved by the FDA in June 2021 for chronic weight management in adults with a BMI of 30 or greater (obesity), or 27 or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or high cholesterol. It is the only semaglutide product with an FDA-approved indication for weight loss. In December 2023, the FDA expanded Wegovy's approval to include cardiovascular risk reduction in overweight/obese adults with established cardiovascular disease, based on the SELECT trial results [5][9].

Ozempic (semaglutide 0.5mg, 1mg, or 2mg injection) was approved in December 2017 for type 2 diabetes management. Ozempic is not FDA-approved for weight loss, but physicians may prescribe it off-label for this purpose. Off-label prescribing is legal and common in the United States — approximately 20% of all prescriptions nationally are written for off-label indications [4]. The key limitation: Ozempic's maximum dose (2mg) is lower than Wegovy's therapeutic weight-loss dose (2.4mg), so patients using Ozempic off-label for weight loss may see somewhat reduced efficacy compared to Wegovy.

Compounded semaglutide is not an FDA-approved product. It is legally produced under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act while semaglutide remains on the FDA's drug shortage list [10]. Section 503A covers traditional compounding pharmacies that fill individual patient prescriptions. Section 503B covers outsourcing facilities that can produce larger batches without individual prescriptions. As of March 2026, semaglutide remains on the shortage list, which is the legal basis for compounding. The FDA has signaled that this designation may be resolved in 2026, which would remove the legal basis for compounding semaglutide and require patients to transition to branded products [10].

In Texas, compounding pharmacies are regulated by the Texas State Board of Pharmacy under Chapter 291, Subchapter H. Texas requires compounding pharmacies to maintain a valid Texas pharmacy license, source active pharmaceutical ingredients from FDA-registered suppliers, maintain beyond-use dating documentation, and submit to periodic inspections [11]. DFW patients should ask their clinic which compounding pharmacy supplies their semaglutide and verify that pharmacy holds both a Texas license and, ideally, FDA 503B registration. Major 503B suppliers used by DFW clinics include Empower Pharmacy (Houston), Hallandale Compounding Pharmacy (Florida), and Olympia Pharmacy (Florida) [6].

Dosing Schedule & Ramp-Up

Semaglutide uses a gradual dose escalation schedule over 16-20 weeks to minimize gastrointestinal side effects. Jumping directly to the therapeutic dose causes significantly more nausea, vomiting, and diarrhea — which is why every major clinical trial and the FDA-approved labeling require a slow ramp-up. Do not skip doses or accelerate the schedule without medical supervision [2][3].

The standard Wegovy escalation schedule is as follows:

Based on FDA-approved Wegovy prescribing information [2]. Compounded semaglutide dosing typically follows the same schedule, though compounding pharmacies may formulate different concentrations per mL.

Why the ramp matters: GLP-1 receptor activation causes the gastrointestinal tract to slow motility (gastric emptying delay) and signals the brain to reduce appetite. When these effects hit at full force without gradual adaptation, patients experience severe nausea, vomiting, and in some cases cannot tolerate the medication at all. The STEP trials found that patients who followed the full 16-week escalation had a 15-20% lower rate of medication discontinuation due to GI side effects compared to historical data from more aggressive dosing protocols [3][7]. The slow ramp also allows the prescribing provider to identify patients who are unusually sensitive to GLP-1 activation before they reach the full dose.

Some patients do not reach or require the full 2.4mg maintenance dose. In clinical practice, a subset of patients (estimated 15-25%) achieve satisfactory appetite suppression and weight loss at 1.0mg or 1.7mg, and their providers hold them at that dose rather than escalating further [2]. A lower maintenance dose means fewer side effects and lower medication cost — particularly relevant for cash-pay DFW patients, since compounded semaglutide pricing at some clinics scales with dose.

In the DFW market, the clinic-administered vs. self-injection split affects the dosing experience. Of the 40 clinics in our database, 4 offer weekly in-clinic monitoring with injections administered by a nurse or medical assistant: Vital Wellness Texas (Dallas and Frisco), Q Day Walk-In Clinic (Plano), and The Aesthetics Society (Southlake) [6]. These clinics typically manage the dose escalation directly, adjusting based on weekly assessments of weight, GI tolerance, and patient-reported appetite. The remaining 36 clinics use monthly monitoring, with patients either self-injecting at home or returning to the clinic once weekly for injection only. Self-injecting patients receive their full month's supply and are responsible for following the dose escalation instructions provided by their clinic.

A practical note for DFW patients: your injection day and time should be consistent each week (for example, every Tuesday morning). If you miss a dose by more than 5 days, do not double up — skip the missed dose and resume your regular schedule the following week. If you miss two or more consecutive doses, contact your prescribing provider, as you may need to restart at a lower dose to avoid rebound GI side effects [2].

Common Side Effects

Gastrointestinal side effects are the most common reason patients discontinue semaglutide. The STEP trial program provides the most comprehensive side-effect data, based on over 8,000 participants receiving semaglutide 2.4mg. The following rates are from the STEP 1 and STEP 2 trials, which tracked adverse events over 68 weeks [3][12].

Data from STEP 1 trial (semaglutide 2.4mg vs placebo, 68 weeks, n=1,961) [3] and STEP 2 trial (n=1,210) [12]. Rates reflect any occurrence during the trial period, not persistent symptoms.

The GI side effects are directly linked to semaglutide's mechanism of action. Nausea and vomiting result from delayed gastric emptying — food sits in your stomach longer, creating a sensation of fullness that can tip into nausea, especially after larger meals. Constipation and diarrhea reflect changes in bowel motility as GLP-1 receptors in the gut adjust to continuous activation. Most patients report that these effects are worst during dose escalation weeks and improve substantially once they stabilize at their maintenance dose [3].

Management strategies recommended by DFW clinics include: eating smaller, more frequent meals rather than large portions; avoiding high-fat and fried foods, which exacerbate nausea with delayed gastric emptying; staying well-hydrated (dehydration worsens constipation and nausea); and timing the injection for the evening so that peak nausea occurs during sleep. Several DFW clinics — including Vital Wellness Texas, Lone Star Medical Associates, and Genesis Lifestyle Medicine — include nutrition counseling as part of their semaglutide program specifically to help patients manage these side effects [6].

Serious but rare side effects require separate consideration. Semaglutide carries an FDA-mandated boxed warning regarding thyroid C-cell tumors. In rodent studies, semaglutide and other GLP-1 agonists caused dose-dependent thyroid C-cell tumors including medullary thyroid carcinoma (MTC). This has not been confirmed in humans, and the relevance to human patients is uncertain — but the precautionary warning stands [2]. Pancreatitis has been reported in 0.2% of semaglutide-treated patients versus 0.1% of placebo patients in clinical trials. Gallbladder-related events (cholelithiasis, cholecystitis) occurred in 2.6% of semaglutide patients versus 1.2% of placebo patients, likely related to rapid weight loss rather than the drug itself [3]. Acute kidney injury has been reported in rare cases, typically secondary to severe dehydration from vomiting or diarrhea [2].

DFW clinics with higher monitoring frequency (weekly visits) are better positioned to catch early warning signs of serious adverse events. Clinics with monthly monitoring rely more heavily on patient self-reporting. Regardless of your clinic's monitoring schedule, contact your prescribing provider immediately if you experience persistent severe abdominal pain (possible pancreatitis), right upper quadrant pain with fever (possible gallbladder disease), significant swelling or lump in the neck (possible thyroid issue), or signs of severe dehydration including decreased urination [2].

Who Should NOT Take Semaglutide

Semaglutide is not appropriate for everyone seeking weight loss. The FDA-approved prescribing information lists specific contraindications (absolute reasons not to use the drug) and precautions (conditions requiring careful risk-benefit assessment with your healthcare provider) [2]. DFW patients should discuss these with their prescribing provider before starting treatment, and any reputable clinic should screen for these conditions during your initial consultation.

Absolute contraindications — do not take semaglutide if you have any of the following:

• Personal or family history of medullary thyroid carcinoma (MTC). Because of the thyroid C-cell tumor signal in rodent studies, semaglutide is contraindicated in patients with a personal history of MTC or a first-degree relative (parent, sibling, child) with MTC [2].
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2). MEN2 is a genetic condition that predisposes to medullary thyroid carcinoma. Patients with MEN2 should not take semaglutide or any GLP-1 receptor agonist [2].
• Known hypersensitivity to semaglutide. Allergic reactions including anaphylaxis and angioedema have been reported rarely. If you had a previous allergic reaction to semaglutide or any component of the formulation, it is contraindicated [2].
• Pregnancy. Semaglutide is contraindicated during pregnancy (Category X equivalent under the new FDA labeling system). Animal studies showed embryofetal toxicity. Women of childbearing potential should use contraception during treatment and discontinue semaglutide at least 2 months before a planned pregnancy, due to the drug's long half-life [2].

Relative contraindications and precautions — use with caution and discuss with your provider:

• History of pancreatitis. GLP-1 agonists have been associated with acute pancreatitis in post-market reports. Patients with a history of pancreatitis may be at elevated risk. If you have had pancreatitis previously, your provider should weigh the benefits of semaglutide against the risk of recurrence [2][3].
• Gallbladder disease. Rapid weight loss increases the risk of gallstones (cholelithiasis). Semaglutide-treated patients had a 2.6% rate of gallbladder events in the STEP 1 trial compared to 1.2% with placebo. Patients with existing gallbladder disease or prior cholecystectomy should be monitored [3].
• Severe gastrointestinal disease. Patients with gastroparesis, inflammatory bowel disease, or a history of bowel obstruction may experience worsened symptoms with semaglutide's gastric-emptying delay. The medication may also interfere with absorption of oral medications in patients with severe GI motility disorders [2].
• Diabetic retinopathy. Rapid improvement in blood glucose control has been associated with temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should have an eye exam before starting semaglutide and be monitored during treatment [4].
• Renal impairment. Semaglutide-related GI events (nausea, vomiting, diarrhea) can cause dehydration, which may worsen kidney function. Patients with chronic kidney disease should be counseled on hydration and monitored with periodic renal function tests [2].
• Concurrent use of insulin or sulfonylureas. Semaglutide can increase the risk of hypoglycemia when combined with insulin or sulfonylureas. Dose adjustments of the existing diabetes medications may be necessary [4].

DFW patients should expect their prescribing clinic to ask about all of the above conditions during the initial consultation. Baseline lab work — including a metabolic panel, thyroid function panel, and lipid panel — is standard practice and helps identify patients at elevated risk. Of the 40 clinics in our DFW database, the majority include baseline labs in their initial visit fee, though some charge separately ($50-150) [6]. For a comprehensive assessment of whether semaglutide is right for you, see our eligibility guide.

What Is Semaglutide FAQ